Suneva Medical Selects Crown Laboratories To Co-Promote ReFissa®
- New relationship will expand the dermatology prescriber base for ReFissa®
- ReFissa® is indicated as an adjunctive agent for the mitigation of fine wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin
- ReFissa® is delivered in a highly emollient base suitable for dry and sensitive skin
SAN DIEGO, March 2, 2015 /PRNewswire/ -- Suneva Medical, Inc., a privately-held aesthetics company, today announced that it has selected Crown Laboratories, Inc., an innovator in solutions for the skin in the United States, to co-promote ReFissa®. ReFissa® [Tretinoin Cream, USP (Emollient) 0.05%] is the only FDA approved and marketed 0.05% tretinoin emollient cream indicated as an adjunctive agent for use in the mitigation of fine wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin in patients who do not achieve such palliation using comprehensive skin care and sun avoidance programs. The relationship between Suneva Medical and Crown Laboratories will expand the awareness and prescriber base of ReFissa® in the U.S. dermatology community.
"Our strategic relationship with Crown Laboratories—an industry leader with expertise that spans the full spectrum of the skin care channel—ensures more health care practitioners can access ReFissa®, a unique and valuable product for the dermatology community treating anti-aging concerns," said Nicholas L. Teti, Jr., Chairman and Chief Executive Officer of Suneva Medical. "The Crown Laboratories partnership is a welcome addition that enhances our footprint across the aesthetics industry."
"Crown Laboratories is very excited about this collaboration with Suneva Medical and the subsequent promotion of ReFissa® to medical dermatologists in the U.S.," stated Gaylord VanGuilder, Vice President, Commercial Operations, Crown Laboratories. "As an aggressive growth company, we continue to make great strides in expanding our commercial presence across multiple segments within the U.S. dermatology market. Our relationship with Suneva is another exciting stride for the company which reinforces our strategic focus and commitment to providing innovative, quality solutions for dermatologists and patients alike."
To learn more about ReFissa®, visit www.refissa.com.
Important Safety Information:
ReFissa® does not eliminate wrinkles, repair sun-damaged skin, reverse photo-aging, or restore more youthful or younger dermal histologic pattern. ReFissa® should be used under medical supervision as an adjunct to a comprehensive skin care program that includes avoiding direct sunlight (by using protective clothing and sunscreens with a minimum SPF of 15) and using other moisturizing facial creams that do not contain tretinoin. The effectiveness of ReFissa® has not been established in people greater than 50 years of age or in people with moderately to heavily pigmented skin. It has not been studied in people with visible actinic keratoses, a history of skin cancer, or during pregnancy. You should not use ReFissa® if you are pregnant or trying to become pregnant. In some cases, ReFissa® may cause redness, dry skin, itching, burning, stinging and peeling. It should be discontinued if hypersensitivity to any of its ingredients is noted. Please see full prescribing information at www.refissa.com.
About Crown Laboratories, Inc.
Crown Laboratories, Inc. is a privately-held, fully integrated, specialty pharmaceutical company dedicated to the development, manufacturing, and commercialization of consumer healthcare products, branded and generic prescription products, and contract development and manufacturing services. For more information, please visit www.crownlaboratories.com.
About Suneva Medical, Inc.
Suneva Medical, Inc. is a privately-held aesthetics company focused on developing, manufacturing and commercializing novel, differentiated products for the general dermatology and aesthetic markets. The innovative aesthetics leader markets Bellafill®, the only dermal filler on the market that is approved by the U.S. Food and Drug Administration for the correction of nasolabial folds and moderate to severe, atrophic, distensible facial acne scars on the cheek in patients over the age of 21 years. In markets outside the U.S., Bellafill® is only approved for the correction of nasolabial folds. The company markets Bellafill® in the U.S. and Canada; ArteFill® in South Korea and Singapore; Regenica® skin care in the U.S. and Canada; and ReFissa® tretinoin cream in the U.S. ArteFill® was rebranded to Bellafill® in the U.S. to reflect the transformational outcomes this unique product can provide to patients seeking correction of their acne scars and nasolabial folds. For more information, visit www.sunevamedical.com.
Logo - http://photos.prnewswire.com/prnh/20150227/178494LOGO
SOURCE Suneva Medical, Inc.
Share this article